Eszopiclone

證據等級: L5

預測適應症: 0 個

Eszopiclone: Sedative-Hypnotic Agent — Insufficient Data for Repurposing Evaluation

One-Sentence Summary

Eszopiclone (DrugBank DB00402) is a non-benzodiazepine sedative-hypnotic known for its use in insomnia treatment. The current Evidence Pack contains no TxGNN-predicted new indications for this compound, and the drug is not marketed in Taiwan. Evaluation cannot advance beyond the preliminary stage due to multiple blocking data gaps, including absent regulatory records, missing mechanism of action data, and no safety information on file.

Quick Overview

Item	Content
Original Indication	Not recorded in current Evidence Pack
Predicted New Indication	None — no TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	N/A (no predictions to evaluate)
Taiwan Market Status	✗ Not marketed
Number of Licenses	0
Recommended Decision	Hold

Taiwan Regulatory Information

Eszopiclone currently holds zero drug licenses (licenses) in Taiwan and has no documented marketing history in this jurisdiction. No dosage form records, brand name registrations, or approved indication texts are available.

This drug is not authorized for use in Taiwan. Any repurposing evaluation would need to account for a full regulatory pathway from scratch.

Safety Considerations

All safety data fields in the current Evidence Pack are absent. No key warnings, contraindications, or drug interaction records were retrieved.

Please refer to the originating country’s package insert (e.g., FDA-approved Lunesta® labeling) for safety information, including CNS depression warnings, complex sleep behavior risk, and dependence potential.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Eszopiclone is critically incomplete — there are no TxGNN repurposing predictions, no Taiwan regulatory records, no mechanism of action data, and no safety information. There is no repurposing candidate to evaluate at this time.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for DB00402 (Eszopiclone) — the predicted_indications array is empty, suggesting the prediction step was not completed or the drug was not matched in the knowledge graph
Verify DrugBank mapping — confirm that DB00402 is correctly linked to the KG node and that run_kg_prediction.py processed it without silent failure
Retrieve MOA data from DrugBank API (DG002: High severity) — eszopiclone acts as a positive allosteric modulator of GABA-A receptors; this should be fetchable and is essential for mechanistic plausibility analysis
Taiwan market assessment — confirm whether eszopiclone is intentionally absent from Taiwan (Health Canada / TFDA) or whether a data retrieval error occurred; note that eszopiclone is approved in the US (Lunesta) and several other markets
Safety data retrieval — download and parse the originating country’s package insert to populate key warnings and contraindications (DG001: Blocking severity)
Re-issue Evidence Pack after above gaps are resolved before proceeding to full repurposing report
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.